Merck & Co Maps Out Route To $10bn Cardiovascular Franchise

Eight Approvals Targeted By 2030

 
• By Andrew McConaghie

The US pharma giant is planning ahead for Keytruda’s swansong, and hopes that wave of new cardiovascular drugs can help maintain its growth into the next decade.

Merck & Co.
Merck & Co. is building q case for a post-Keytruda portfolio including big-earning cardiovascular drugs, but analysts are yet to buy into its $10bn plus projections. • Source: Alamy

More from Business

More from Scrip